Table 1.
Clinicopathological and treatment characteristics according to the performance of re-excision in the total cohort (n = 32119)
| Primary BCS only | Primary BCS + re-excision by BCS | Primary BCS + re-excision by mastectomy | p valuea | |
|---|---|---|---|---|
| No. of patients | 25878 (80.6) | 2368 (7.4) | 3873 (12.1) | |
| Age | <0.001 | |||
| >60 years | 10505 (40.6) | 718 (30.3) | 1185 (30.6) | |
| 51–60 years | 7946 (30.7) | 780 (32.9) | 1113 (28.7) | |
| 41–50 years | 5795 (22.4) | 681 (28.8) | 1152 (29.7) | |
| ≤40 years | 1632 (6.3) | 189 (8.0) | 423 (10.9) | |
| Histology | <0.001 | |||
| Ductal | 20148 (77.9) | 1797 (77.9) | 2548 (65.8) | |
| Lobularb | 2841 (11.0) | 325 (13.7) | 901 (23.3) | |
| Other | 2889 (11.2) | 246 (10.4) | 424 (10.9) | |
| Differentiation grade | <0.001 | |||
| 1 | 6657 (25.7) | 550 (23.2) | 606 (15.6) | |
| 2 | 10726 (41.4) | 985 (41.6) | 1611 (41.6) | |
| 3 | 7086 (27.4) | 657 (27.7) | 1281 (33.1) | |
| Unknown | 1409 (5.4) | 176 (7.4) | 375 (9.7) | |
| pT | <0.001 | |||
| T1 | 19289 (74.5) | 1730 (73.1) | 2164 (55.9) | |
| T2 | 6463 (25.0) | 631 (26.6) | 1493 (38.5) | |
| T3 | 51 (0.2) | 6 (0.3) | 216 (5.6) | |
| ypT0 | 75 (0.3) | 1 (0.0) | – | |
| pN | <0.001 | |||
| N0 | 18200 (70.3) | 1589 (67.1) | 1998 (51.6) | |
| N1 | 5944 (23.0) | 620 (26.2) | 1284 (33.2) | |
| N2 | 1045 (4.0) | 104 (4.4) | 375 (9.7) | |
| N3 | 432 (1.7) | 35 (1.5) | 183 (4.7) | |
| Unknown | 257 (1.0) | 20 (0.8) | 33 (0.9) | |
| Oestrogen receptor | <0.001 | |||
| Positive | 13508 (52.2) | 1267 (53.5) | 1803 (46.6) | |
| Negative | 2720 (10.5) | 230 (9.7) | 422 (10.9) | |
| Unknown | 9650 (37.3) | 871 (36.8) | 1648 (42.6) | |
| Progesterone receptor | <0.001 | |||
| Positive | 10836 (41.9) | 996 (42.1) | 1414 (36.5) | |
| Negative | 4874 (18.8) | 424 (17.9) | 725 (18.7) | |
| Unknown | 10168 (39.3) | 948 (40.0) | 1734 (44.8) | |
| HER2Neu receptor | <0.001 | |||
| Negative | 13282 (51.3) | 1220 (51.5) | 1647 (42.5) | |
| Positive | 1761 (6.8) | 183 (7.7) | 404 (10.4) | |
| Unknown | 10835 (41.9) | 965 (40.8) | 1822 (47.0) | |
| Systemic therapyc | <0.001 | |||
| None | 13128 (51.1) | 1114 (47.0) | 1321 (34.1) | |
| Chemotherapy only | 3173 (12.3) | 286 (12.1) | 565 (14.6) | |
| Hormonal therapy only | 4038 (15.6) | 332 (14.0) | 616 (15.9) | |
| Chemotherapy and hormonal therapy | 5449 (21.1) | 636 (26.9) | 1371 (35.4) | |
pT pathological tumor stage, pN regional lymph nodes stage
a χ 2 test
bIncludes mixed ductal and lobular tumors
cBoth neoadjuvant and adjuvant